VEGF C-D
Neovascular Age-Related Macular Degeneration (nAMD)
Phase 2/3Active
Key Facts
Indication
Neovascular Age-Related Macular Degeneration (nAMD)
Phase
Phase 2/3
Status
Active
Company
About Regeneron
Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.
View full company profileTherapeutic Areas
Other Neovascular Age-Related Macular Degeneration (nAMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DE-130 (Eylea biosimilar) | Santen Pharmaceutical | Phase 3 |